Literature DB >> 19383975

The pharmacology of mTOR inhibition.

David A Guertin1, David M Sabatini.   

Abstract

A flurry of reports indicates that we are entering a new phase in the development of mammalian target of rapamycin (mTOR)-based therapies for oncology. Here, we summarize exciting findings regarding mTOR signaling and the outlook for mTOR inhibitors as tools to study the mTOR pathway and as drugs in the clinic.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19383975     DOI： 10.1126/scisignal.267pe24

Source DB:  PubMed          Journal:  Sci Signal        ISSN： 1945-0877            Impact factor:   8.192


  272 in total

1.  Human immunodeficiency virus-1 inhibition of immunoamphisomes in dendritic cells impairs early innate and adaptive immune responses.

Authors:  Fabien P Blanchet; Arnaud Moris; Damjan S Nikolic; Martin Lehmann; Sylvain Cardinaud; Romaine Stalder; Eduardo Garcia; Christina Dinkins; Florence Leuba; Li Wu; Olivier Schwartz; Vojo Deretic; Vincent Piguet
Journal:  Immunity       Date:  2010-05-06       Impact factor: 31.745

Review 2.  Utility of mTOR inhibition in hematologic malignancies.

Authors:  Anas Younes; Nousheen Samad
Journal:  Oncologist       Date:  2011-05-31

3.  S6 kinase 1 is required for rapamycin-sensitive liver proliferation after mouse hepatectomy.

Authors:  Catherine Espeillac; Claudia Mitchell; Séverine Celton-Morizur; Céline Chauvin; Vonda Koka; Cynthia Gillet; Jeffrey H Albrecht; Chantal Desdouets; Mario Pende
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

4.  Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance.

Authors:  Kazuhiro Tanaka; Ivan Babic; David Nathanson; David Akhavan; Deliang Guo; Beatrice Gini; Julie Dang; Shaojun Zhu; Huijun Yang; Jason De Jesus; Ali Nael Amzajerdi; Yinan Zhang; Christian C Dibble; Hancai Dan; Amanda Rinkenbaugh; William H Yong; Harry V Vinters; Joseph F Gera; Webster K Cavenee; Timothy F Cloughesy; Brendan D Manning; Albert S Baldwin; Paul S Mischel
Journal:  Cancer Discov       Date:  2011-09-13       Impact factor: 39.397

5.  Mammalian target of rapamycin in spinal cord neurons mediates hypersensitivity induced by peripheral inflammation.

Authors:  E Norsted Gregory; S Codeluppi; J A Gregory; J Steinauer; C I Svensson
Journal:  Neuroscience       Date:  2010-06-09       Impact factor: 3.590

6.  Targeted immunosuppression: no longer naïve.

Authors:  Robert S Hagan; Jonathan D Powell
Journal:  Clin Immunol       Date:  2011-10-25       Impact factor: 3.969

7.  Non-small cell lung carcinoma therapy using mTOR-siRNA.

Authors:  Hirochika Matsubara; Kenji Sakakibara; Tamo Kunimitsu; Hiroyasu Matsuoka; Kaori Kato; Noboru Oyachi; Yoh Dobashi; Masahiko Matsumoto
Journal:  Int J Clin Exp Pathol       Date:  2012-02-12

8.  Identification of a small molecule yeast TORC1 inhibitor with a multiplex screen based on flow cytometry.

Authors:  Jun Chen; Susan M Young; Chris Allen; Andrew Seeber; Marie-Pierre Péli-Gulli; Nicolas Panchaud; Anna Waller; Oleg Ursu; Tuanli Yao; Jennifer E Golden; J Jacob Strouse; Mark B Carter; Huining Kang; Cristian G Bologa; Terry D Foutz; Bruce S Edwards; Blake R Peterson; Jeffrey Aubé; Margaret Werner-Washburne; Robbie J Loewith; Claudio De Virgilio; Larry A Sklar
Journal:  ACS Chem Biol       Date:  2012-02-01       Impact factor: 5.100

Review 9.  Emergence of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin axis in transforming growth factor-β-induced epithelial-mesenchymal transition.

Authors:  Samy Lamouille; Rik Derynck
Journal:  Cells Tissues Organs       Date:  2010-11-02       Impact factor: 2.481

10.  Phosphorylation of p53 by TAF1 inactivates p53-dependent transcription in the DNA damage response.

Authors:  Yong Wu; Joy C Lin; Landon G Piluso; Joseph M Dhahbi; Selene Bobadilla; Stephen R Spindler; Xuan Liu
Journal:  Mol Cell       Date:  2013-11-27       Impact factor: 17.970
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.